2-bromo-2-cyclohexyl-1-phenylethanone | 36677-66-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-bromo-2-cyclohexyl-1-phenylethanone
• 英文别名: 2-Bromo-2-cyclohexyl-1-phenylethanone
• CAS: 36677-66-4
• 化学式: C₁₄H₁₇BrO
• 分子量: 281.192
• InChiKey: NODQISXANKQTQO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-bromo-2-cyclohexyl-1-phenylethanone 在 水 、 potassium carbonate 、 potassium hydroxide 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 21.33h， 生成 3-cyclohexyl-1-methyl-2-phenyl-1H-imidazo[1,2-b]pyrazole-7-carboxylic acid
  参考文献：
  名称：

  [EN] COMPOUNDS FOR THE TREATMENT OF HCV
  [FR] COMPOSÉS POUR LE TRAITEMENT DES INFECTIONS PAR VHC

  摘要：

  本发明涉及式(I)的病毒聚合酶抑制剂、其盐、溶剂化物、水合物、外消旋混合物、对映异构体和同分异构体，尤其是流感病毒科（Flaviviridae）内的病毒聚合酶抑制剂，如丙型肝炎病毒（HCV），其制备过程以及它们在治疗流感病毒科病毒感染，如丙型肝炎病毒（HCV）感染中的用途。

  公开号：

  WO2013036994A1
• 作为产物：
  描述：

  环己氯化镁 在 溴 、 zinc(II) chloride 作用下， 以 1,4-二氧六环 、 乙醚 为溶剂， 反应 21.0h， 生成 2-bromo-2-cyclohexyl-1-phenylethanone
  参考文献：
  名称：

  [EN] COMPOUNDS FOR THE TREATMENT OF HCV
  [FR] COMPOSÉS POUR LE TRAITEMENT DES INFECTIONS PAR VHC

  摘要：

  本发明涉及式(I)的病毒聚合酶抑制剂、其盐、溶剂化物、水合物、外消旋混合物、对映异构体和同分异构体，尤其是流感病毒科（Flaviviridae）内的病毒聚合酶抑制剂，如丙型肝炎病毒（HCV），其制备过程以及它们在治疗流感病毒科病毒感染，如丙型肝炎病毒（HCV）感染中的用途。

  公开号：

  WO2013036994A1

文献信息

• One-Pot Synthesis Using the Supported Reagent System Na₂CO₃/SiO₂-PPA/SiO₂: Synthesis of Benzo[<i>b</i>]thiophenes and Naphthothiophenes
  作者：Tadashi Aoyama、Mami Orito、Toshio Takido、Mitsuo Kodomari

  DOI：10.1055/s-2008-1067105

  日期：——

  method has been developed for the synthesis of benzo[ B]thiophenes and naphtho[2,1- B]thiophenes from arenethiols and α-halo ketones using Na 2 CO 3 /SiO 2 -PPA/SiO 2 . Reaction of α-halo ketones with arenethiols is promoted by Na 2 CO 3 /SiO 2 to afford α-sulfanyl ketones, which cyclize in the presence of PPA/SiO 2 to give the corresponding thiophene-fused arenes in one-pot. The reaction using α-bromo acetals

  开发了一种简单有效的方法，用于使用 Na 2 CO 3 /SiO 2 -PPA/SiO 2 从芳硫醇和α-卤代酮合成苯并[B]噻吩和萘并[2,1-B]噻吩。Na 2 CO 3 /SiO 2 促进α-卤代酮与芳烃硫醇反应生成α-硫烷基酮，在PPA/SiO 2 存在下环化生成相应的噻吩稠合芳烃一锅法。使用α-溴缩醛代替α-卤代酮的反应也通过一锅三步反应得到相应的萘并[2,1-B]噻吩。
• SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES
  申请人：Masarykova univerzita

  公开号：EP3556756A1

  公开（公告）日：2019-10-23

  The invention provides compounds represented by the structural formula (1): wherein R1, R2, R3, R4, R5, R6 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.

  本发明提供了结构式（1）所代表的化合物： 其中 R1、R2、R3、R4、R5、R6 如权利要求中定义。这些化合物是核酸酶的抑制剂，特别适用于增殖性疾病、神经退行性疾病和其他基因组不稳定性相关疾病的治疗和/或预防方法。
• Structural Modification of the Designer Stimulant α-Pyrrolidinovalerophenone (α-PVP) Influences Potency at Dopamine Transporters
  作者：R. Kolanos、F. Sakloth、A. D. Jain、J. S. Partilla、M. H. Baumann、R. A. Glennon

  DOI：10.1021/acschemneuro.5b00160

  日期：2015.10.21

  alpha-Pyrrolidinovalerophenone (alpha-PVP, 7) is an illegal synthetic stimulant that is being sold on the clandestine market as "flakka" and "gravel". The potent pharmacological effects of alpha-PVP are presumably mediated by inhibition of dopamine uptake at the dopamine transporter (DAT). However, little is known about how structural modification of alpha-PVP influences activity at DAT. Eleven analogs of alpha-PVP were synthesized and examined for their ability to inhibit uptake of [H-3]clopamine and [H-3]serotonin in rat brain synaptosomes. None of the analogs significantly inhibited [H-3]serotonin uptake when tested at 10 mu M at the serotonin transporter (SERT). All of the analogs behaved as DAT reuptake inhibitors, but potencies varied over a >1500-fold range. Potency was primarily associated with the nature of the alpha-substituent, with the more bulky substituents imparting the highest potency. Expansion of the pyrrolidine ring to a piperidine reduced potency up to 10-fold, whereas conformational constraint in the form of an aminotetralone resulted in the least potent compound. Our study provides the first systematic and comparative structure activity investigation on the ability of alpha-PVP analogs to act as inhibitors of DAT.
• [EN] COMPOUNDS FOR THE TREATMENT OF HCV<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DES INFECTIONS PAR VHC
  申请人：BIOTA SCIENT MANAGEMENT

  公开号：WO2013036994A1

  公开（公告）日：2013-03-21

  The present invention relates to viral polymerase inhibitors of formula (I), salts, solvates, hydrates, racemates, enatiomers and isomers thereof, in particular inhibitors of viral polymerases within the Flaviviridae family such as hepatitis C virus (HCV), processes for their preparation and their use in the treatment of Flaviviridae viral infection such as Hepatitis C virus (HCV) infections.

  本发明涉及式(I)的病毒聚合酶抑制剂、其盐、溶剂化物、水合物、外消旋混合物、对映异构体和同分异构体，尤其是流感病毒科（Flaviviridae）内的病毒聚合酶抑制剂，如丙型肝炎病毒（HCV），其制备过程以及它们在治疗流感病毒科病毒感染，如丙型肝炎病毒（HCV）感染中的用途。